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Background: Alterations in postprandial metabolism have been described in familial combined hyperlipidemia
(FCH); however, their underlying mechanisms are not well characterized. We aimed to identify factors related to the
magnitude of postprandial lipemia and apolipoprotein (apo) A-V levels in subjects with FCH.
Methods: FCH cases (n = 99) were studied using a standardized meal test. Abdominal obesity was assessed using
the waist to hip ratio (WHR). A linear regression model was performed to investigate the variables associated with
the triglycerides incremental area under the curve (iAUC). Independent associations between metabolic variables
and apo A-V iAUC were also investigated in a randomly selected subgroup (n = 44). The study sample was classified
according to the presence of fasting hypertriglyceridemia (≥150 mg/dL) and abdominal obesity (WHR ≥0.92 in men
and ≥0.85 in women) to explore differences in parameters.
Results: The fasting apo B-48 levels (r = 0.404), and the WHR (r = 0.359) were independent factors contributing to
the triglycerides iAUC (r2 = 0.29, P < 0.001). The triglycerides iAUC was independently associated with the apo A-V
iAUC (r2 = 0.54, P < 0.01). Patients with both hypertriglyceridemia and abdominal obesity showed the most robust
triglycerides and apo A-V postprandial responses.
Conclusions: In patients with FCH the fasting apo B-48 level is the main factor associated with postprandial lipemia.
Abdominal obesity also contributes to the magnitude of the postprandial response.
The triglycerides postprandial increment is the principal factor associated with the apo A-V postprandial response.
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Postprandial lipemia refers to the increment of triglycer-
ides rich lipoproteins (TRL) in plasma after a meal. This
process is associated with an increase in very low dens-
ity lipoproteins (VLDL) that are transformed to low
density lipoproteins (LDL) and delivered to the arterial
wall, a decrease of high-density lipoprotein (HDL)
particle number and function, and production of small-
dense LDL. This unfavorable lipid profile increases car-
diovascular disease (CVD) risk [1]. Postprandial lipemia* Correspondence: caguilarsalinas@yahoo.com
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article, unless otherwise stated.magnitude is affected by the degree of secretion of TRL
and their rate of clearance [2].
Fasting triglycerides concentration represents the main
determinant of postprandial lipemia, explaining around
30% of the variance [3,4]. In selected populations, an-
thropometric characteristics, insulin, HDL-cholesterol
(HDL-c), and apolipoprotein (apo) A-IV, have also been
identified as determinants of postprandial lipemia [5,6].
Recent studies have suggested a role for apo A-V in
modulating triglycerides metabolism [7]. Firstly, it pro-
motes a greater interaction between TRL and lipoprotein
lipase (LPL), increasing their hydrolysis. Secondly, apo
A-V promotes liver triglyceride synthesis [8].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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common genetic form of dyslipidemia [9]. It is associ-
ated with a 1.7- to 10-fold increased risk for CVD [10].
Disturbances of lipid metabolism in FCH are complex.
Dyslipidemia in patients with FCH is characterized by
an overproduction and a delayed catabolism of VLDL
[11]. Patients with FCH exhibit a high VLDL level and
an exaggerated postprandial lipemia. The specific mech-
anisms contributing to postprandial lipemia in FCH are
not well established.
In this study we explored the factors associated with
postprandial lipemia in patients with FCH and whether
the metabolic phenotype alters the magnitude of this
phenomenon. We first analyzed the determinants of
postprandial triglycerides incremental area under the
curve (iAUC). Subsequently, in a randomly selected sub-
group, we investigated factors associated with fasting and
postprandial Apo A-V. Finally, we classified participants
according to the presence of fasting hypertriglyceridemia
(HTG) and increased waist to hip ratio (WHR) in order
to evaluate if the metabolic phenotype modulated the
magnitude and time-sequence of the triglycerides iAUC.
Methods
Study subjects
The study population was selected from an out-patient
cohort of families with FCH identified at the Instituto
Nacional de Ciencias Medicas y Nutricion in Mexico
City. None of the subjects were taking lipid-lowering
therapy mainly because they were newly diagnosed. FCH
was diagnosed using the following criteria: 1) LDL-
cholesterol and/or triglycerides concentrations >160 mg/
dL and >150 mg/dL, respectively; 2) at least one first-
degree relative with hyperlipidemia with a different lipid
phenotype, and 3) a concentration of apo B > the 90th
percentile for the Mexican population (>108 mg/dL and
>99 mg/dL in men and women, respectively) [12-14]. All
study subjects had apo B levels over the 90th percentile
for the Mexican population and HTG and/or hyperchol-
esterolemia at diagnosis; however, some of them showed
inferior levels at the time of the study due to the already
known variability in the lipid profile associated with
FCH. None of the subjects had evidence of chronic ill-
nesses or significant organ dysfunction. Subjects were
weight-stable (<2 kg change) for at least 6 months before
entering the study. We excluded subjects with diabetes
mellitus, fasting triglycerides ≥1000 mg/dL, body mass
index (BMI) ≥40 kg/m2, alcohol consumption >10 g/day
in women and >20 g/day in men, or currently taking
medications known to affect lipid metabolism. Individ-
uals with other primary or secondary dyslipidemias were
also excluded.
The Comite de Etica en Investigacion del Instituto
Nacional de Ciencias Medicas y Nutricion SalvadorZubiran approved the protocol and informed consent
was obtained from all subjects.
Experimental procedures
Subjects completed a comprehensive medical evaluation,
including a history and physical examination. Anthropo-
metric measurements including height, weight, waist,
and hip circumference, systolic and diastolic blood pres-
sures were measured following standardized procedures.
Meal test
Subjects were asked to attend after a 12-hour fasting
period, and a standardized meal was provided. Blood sam-
ples were then obtained at 0 (fasting), 3, 4, 6, and 8 hours
after meal ingestion [15]. The meal consisted of one quar-
ter pounder with cheese hamburger with 5 grams of may-
onnaise, 71 grams of fries, and 250 ml of milk. The energy
content of the meal is 919 kcal and the composition 50%
(51 g) fat, 32.7% (75 g) carbohydrates, and 17.3% (40 g)
protein. After ingestion of the meal subjects were allowed
to drink only water.
Sample analysis
Blood samples were collected in EDTA-containing tubes.
Levels of triglycerides, total cholesterol, HDL-cholesterol
(HDL-c), glucose, aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), and gamma glutamyltransfer-
ase (GGT) were measured by automated enzymatic assays
(Beckman Synchron CX, Brea, CA). LDL-cholesterol (LDL-
c) was calculated by the Friedewald formula [16] when the
fasting triglycerides levels were <300 mg/dL. Insulin levels
were determined utilizing micro-particle enzymatic im-
munoanalysis (MEIA) (Axym System Abbot, Green Oaks,
IL) and apo B levels by kinetic nephelometry (Beckman
Immage, Brea, CA). In a randomly selected subgroup,
apo A-V and apo B-48 concentrations were measured at
the University of Helsinki using ELISA assays (Millipore,
MA, USA and Shibayagi Co., Shibukawa, Gunma, Japan,
respectively).
Calculations
The iAUC over the 8-hour period was calculated using
the trapezoidal method by subtracting the fasting con-
centration from the total AUC. To evaluate insulin sen-
sitivity the homeostasis model assessment (HOMA-IR)
index and the Matsuda index were calculated [17-19].
Statistical analysis
Data were examined for normality with the Shapiro-Wilk
test. Continuous variables are reported as mean ± SD
(standard deviation) or median and [interquartile range
(IQR)] as appropriate. Categorical variables are reported
as frequencies and percentages. Friedman tests were per-
formed to examine the triglycerides, apo B-48, and apo
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formation of non-normal distributed variables, Pearson
correlations were calculated and stepwise multiple linear
regression models were constructed to investigate the in-
dependent predictors of the iAUC of triglycerides and
apo A-V. In the first model, the dependent variable was
the triglycerides iAUC and the independent variables
were the fasting apo B-48, fasting triglycerides, time of
triglycerides peak, WHR, HOMA-IR, and the apo B. In
the second model, the dependent variable was the apo A-
V iAUC. This model included the triglycerides iAUC, apo
B-48 iAUC, fasting triglycerides, apo B, and HDL-c as in-
dependent variables.
The population was then classified into four groups
according to the presence or absence of HTG (fasting
triglycerides level ≥150 mg/dL and <150 mg/dL, re-
spectively) and abdominal obesity (defined using the
median WHR of the population, ≥0.92 in men and ≥0.85
and women). One way ANOVA or Kruskal Wallis
tests were performed to examine differences between
these groups as appropriate. If significance was achievedTable 1 Subjects characteristics
Parameters All cohort (n = 99)
Gender (male/female) 33/66
Age (years) 45.4 ± 13.5
BMI (kg/m2)a 27.1 [25–29.9]
Waist circumference (cm) 89.1 ± 10.6
WHR 0.88 ± 0.07
Systolic blood pressure (mmHg) 120 [110–125]
Diastolic blood pressure (mmHg) 80 [70–80]
Triglycerides (mg/dL) 201.5 [135.5–309]
CholedL)/dL) 219.6 ± 37
HDL-c (mg/dL) 42 [36–51]
LDL-c (mg/dL)b 131.4 ± 30.9
Non HDL-c (mg/dl) 175.7 ± 35.9
Apo B (mg/dL) 115.1 ± 25.6
Apo B-48 (μg/mL) -
Apo A-V (ng/mL) -
Glucose (mg/dL) 97 [92–107]
Insulin (μU/mL) 9.5 [6.8–12.3]
HOMA-IR 2.3 [1.5–3.2]
Matsuda index 30.5 [20.3–39.7]
AST (IU/L) 26 [23–32]
ALT (IU/L) 24.5 [17–34]
GGT (IU/L) 22 [15–37]
Data expressed as means ± SD or medians [IQR].
a The weight in kilograms divided by the square of the height in meters.
b Estimated in 75 subjects with triglycerides levels <300 mg/dl.
Baseline characteristics of study subjects and of the apo A-V and apo B-48 subgrou(P value <0.05) comparisons between individual groups
were performed with independent T test or Mann–
Whitney U test as appropriate. Statistical analyses were
performed using SPSS software version 19.0 (Armonk, NY).
A P value <0.05 (two tailed) was considered statistically
significant.
Results
Baseline characteristics
Of the 106 subjects recruited, seven were excluded; this
was due to an unconfirmed diagnosis of FCH (n = 5),
presence of undiagnosed diabetes (n = 1), and an ele-
vated fasting triglycerides concentration (n = 1). The
characteristics of the 99 individuals participating in the
study are summarized in Table 1. They were 45.4 ±
13.5 years old, with overweight (median BMI of 27.1
[25–29.9] kg/m2), and had a mean waist circumference
of 89.1 ± 10.6 cm. The baseline characteristics of the
randomly selected subgroup (n = 44) used for apo A-V
and apo B-48 analysis were similar in comparison with
the whole cohort (Table 1).Subgroup (n = 44) P
13/31 0.471
46.0 ± 11.6 0.710
27.0 [25.2–30.5] 0.742
88.0 ± 11.0 0.358
0.86 ± 0.07 0.070
120 [110–125] 0.742
77.5 [70–83] 0.462
197.0 [131.0–318.0] 0.555
212.6 ± 32 0.118
39 [34–45] 0.052
133.4 ± 24.5 0.863
174.4 ± 32.1 0.757
116.9 ± 27.2 0.556
5.3 [3–7.4] -
303.3 [268.4–390.3] -
94.0 [88–100] 0.054
9.5 [7.0–12.6] 0.932
2.1 [1.4–3.2] 0.390
32.7 [22.1–49.1] 0.259
26 [23–32] 0.914
22 [17–34] 0.291
20 [14–34] 0.322
p.
Figure 1 Triglycerides, apo B-48, and apo A-V levels during the
meal test. Box plots showing median levels of triglycerides, apo
B-48, and apo A-V concentrations after the meal test. Boxes show
interquartile ranges, and bars represent highest and lowest values
(P < 0.001 for all with Friedman test).
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After the meal challenge, plasma triglycerides, apo B-
48, and apo A-V concentrations increased significantly
(P < 0.001) (Figure 1). Median peak level of triglycer-
ides was 367 mg/dL [241.5–510.5]; this was observed
at 4 hours in 30.3%, and at 3 hours in 25.3% of the popu-
lation. At the end of the sampling period, triglycerides
concentrations returned to baseline only in 25% of the
study subjects. On the other hand, the median apo B-48
peak concentration was 11.7 μg/mL [5.5- 16.3] and the
time to peak was at 4 hours in 33%, and at 6 hours in
26% of the population. In the majority of patients (83%)
levels remained above baseline after eight hours. In
addition, the median apo A-V peak concentration was
478.4 ng/dL [378.6–611.7]. This was observed at 4 hours
in 42%, and at 6 hours in 28% of cases. In 67%, concen-
trations did not reach baseline levels after 8 hours. These
results are summarized in Figure 1.
We calculated the apo B48/apo B index, at baseline
and at eight hours following the test meal, as a measure
of the contribution of chylomicron particles to postpran-
dial lipemia. This index showed a significant change
(0.04 [0.03–0.06] vs. 0.06 [0.03–0.11], P < 0.001), repre-
senting the chylomicrons increase in response to the
meal ingestion.
The fasting and 8-hour apo A-V/triglycerides ratio was
estimated to evaluate the change in this index associated
with the chylomicrons response after ingestion of the
meal. We did not find a significant change in this index
comparing the fasting state and 8 hours after ingestion
of the meal (1.6 [1.0–2.2] and 1.5 [1.1–2.1], respectively,
P = 0.080).
Factors associated with postprandial lipemia
The triglycerides iAUC showed a significant correlation
with the fasting apo B-48 and the fasting triglycerides
concentrations (r = 0.43, P = 0.004 and r = 0.39, P < 0.001,
respectively). In addition, significant positive correlations
were found between the triglycerides iAUC and the time
of triglycerides peak (r = 0.35, P < 0.001), WHR (r = 0.30,
P = 0.003), apo B (r = 0.24, P = 0.017), BMI (r = 0.24, P =
0.017), and HOMA-IR (r = 0.23, P = 0.022). A significant
negative correlation was identified between Matsuda
index and the triglycerides iAUC (r = −0.20, P = 0.045).
Despite a positive correlation between the triglycerides
iAUC and the apo B-48 iAUC (r = 0.44, P = 0.004), we
did not find significant correlations between the apo
B-48 iAUC and the studied variables.
Independent factors associated with post-prandial
triglycerides response
The linear regression analysis identified the fasting apo
B-48 levels (r = 0.40), and the WHR (r = 0.35) as inde-
pendent parameters determining the triglycerides iAUC,explaining 29% of the variability. The model also in-
cluded the fasting triglycerides concentration, time of tri-
glycerides peak, HOMA-IR, and the apo B levels, none of
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ation with the triglycerides iAUC (Table 2).
Factors associated with fasting and postprandial apo A-V
levels
We explored associations between the fasting apo A-V
concentration, apo A-V iAUC, and anthropometric and
metabolic parameters. The fasting apo A-V concentration
showed significant correlations with the fasting triglycer-
ides levels (r = 0.39, P = 0.010) and apo B levels (r = 0.32,
P = 0.032).
The apo A-V iAUC showed significant associations with
the triglycerides iAUC (r = 0.72, P < 0.001), apo B levels
(r = 0.52, P = 0.001), apo B-48 iAUC (r = 0.47, P = 0.004),
and fasting triglycerides levels (r = 0.46, P = 0.004). A nega-
tive correlation between the apo A-V iAUC and HDL-c
was also found (r = −0.36, P = 0.028).
Independent factors associated with postprandial apo A-V
response
In the linear regression model, the only variable inde-
pendently associated with the apo A-V iAUC was the tri-
glycerides iAUC, explaining 54.4% of the variability in
this variable (P < 0.001). This model also included the
apo B-48 iAUC, fasting triglycerides, apo B, and HDL-c
levels as independent variables. When the triglycerides
iAUC was removed from this model, the apo B-48 iAUC,
apo B, and HDL-c were associated with the postprandial
apo A-V response, explaining 51.1% of the variability in
this parameter.
Parameters according to the presence or absence of
fasting hypertriglyceridemia and abdominal obesity
Individuals were classified in four groups according to
the level of fasting triglycerides and the median WHR as
follows: 1) HTG (≥150 mg/dL) with abdominal obesity
(WHR ≥0.92 in men and ≥0.85 in women), 2) HTG with-
out abdominal obesity, 3) normotriglyceridemia (NTG)
(<150 mg/dl) with abdominal obesity, and 4) NTG with-
out abdominal obesity. The characteristics of these
groups are shown in Table 3.
Individuals with fasting HTG and abdominal obesity,
showed the highest triglycerides iAUC, and the time to
triglycerides peak concentration was later (median
5 hours) than in the other groups. In this group apo B-48Table 2 Linear regression model
Independent variables β Standardized β
Fasting apo B-48 0.512 0.377
WHR 4.885 0.328
r2 = 0.29, F = 7.97, P < 0.001.
Dependent variable: triglycerides iAUC; variables included in the model: fasting apo
HOMA-IR, and waist to hip ratio (WHR).
Stepwise linear regression analysis showing independent variables associated withpeak concentrations were also higher. Triglycerides peak
level was higher in the groups with fasting HTG in com-
parison with the groups with normal fasting triglycerides
concentration. The apo B-48 iAUC showed a tendency to
be higher in groups with fasting hypertriglyceridemia.
The highest apo A-V iAUC and peak concentrations were
observed in the HTG with abdominal obesity group, fol-
lowed by the group with HTG without abdominal obesity.
The group without any of the abnormalities showed the
shortest time to peak apo A-V levels. In contrast, the group
with both HTG and abdominal obesity showed a later peak.
These results are summarized in Figure 2 and Table 3.
Discussion
The lipoproteins and mechanisms that modulate post-
prandial lipemia in patients with FCH are not well
understood. We studied a cohort of patients with FCH
to determine factors related to postprandial lipemia. Our
results show that the magnitude of the triglycerides
iAUC is determined by the fasting apo B-48 concentra-
tion and the WHR. In our second linear regression
model the postprandial apo A-V levels were only associ-
ated with the triglycerides iAUC. When the study popu-
lation was classified according to the fasting triglycerides
level and the WHR, the most robust postprandial tri-
glycerides response was observed in the group with fast-
ing HTG and abdominal obesity.
These results indicate that the magnitude of the post-
prandial lipemia in patients with FCH is determined by
the fasting apo B-48 concentration and potentiated by
the presence of abdominal obesity. However, the linear
regression model explained only a modest proportion of
the variability in postprandial lipemia; therefore, add-
itional variables related to this phenomenon may be
involved.
Interestingly, the apo B-48 postprandial response,
reflecting the chylomicrons rise after the meal, was not
independently associated with abdominal obesity or
fasting hypertriglyceridemia. This result indicates that
in patients with FCH the chylomicron response is not
determined by the same parameters that influence the
postprandial triglycerides iAUC (fasting apo B-48 levels
and abdominal obesity).
In contrast to our results, other studies including indi-
viduals with diverse cardiovascular risk have reportedt P Partial correlations
2.45 0.009 0.404
2.4 0.021 0.359
B-48, fasting triglycerides, time of triglycerides peak, apolipoprotein B,
postprandial triglycerides levels in FCH.
Table 3 Subjects subgroups characteristics
Variable HTG with
obesity (n = 48)
HTG without
obesity (n = 21)
NTG with
obesity (n = 13)
NTG without
obesity (n = 17)
P
WHR 0.92 ± 0.05c, e 0.82 ± 0.04d 0.91 ± 0.04e 0.80 ± 0.03 <0.001
Fasting parametersa
Triglycerides (mg/dL) 275 [201–345]d, e 271 [185–346]d, e 126 [103–136] 105 [79–131] <0.001
Cholesterol (mg/dL) 226.9 ± 37.2d, e 228.8 ± 38.9 206.3 ± 18.9 197.5 ± 34.9 0.010
LDL-c (mg/dL) 129.4 ± 26.4 141.9 ± 44.7 133.7 ± 16.7 129.3 ± 24.9 0.604
Non HDL-c (mg/dL) 173.3 ± 27.2 181.6 ± 41.7d, e 157.7 ± 16.1 150 ± 29.4 0.014
Apo B (mg/dL) 123.2 ± 24.9d, e 122.3 ± 23.1 109.1 ± 11.8 107.3 ± 24.2 <0.001
Apo B-48 (μg/mL)b 6.5 [5.4–8.9]d, e 6.7 [3–7.4]d 1.5 [0.9–2.9] 3.1 [1.3–4.6] <0.001
Apo A-V (ng/mL)b 365.5 303.3 215.5 287.9 0.096
[301.7–408.3] [268.4–374.3] [187.5–326.2] [267.5–329.8]
Glucose (mg/dL) 103 [95–110]d, e 97 [92–107] 96 [91–101] 91 [87–94] 0.001
Insulin (μU/mL) 11.15 [7.7–13.4]d, e 8.6 [5.6–12.6] 7.6 [6.1–9.5] 8.9 [5.1–9.8] 0.029
HOMA-IR 2.73 [1.91–3.61]d, e 2.03 [1.45–3.21] 1.89 [1.41–2.5] 2.04 [1.28–2.29] 0.010
AST (IU/L) 30 [25–33]d 26 [24–33] 25 [21.5–28] 25 [22–27] 0.073
ALT (IU/L) 30 [21–37]d, e 22 [18–34] 19.5 [15–25] 20 [16–30] 0.015
GGT (IU/L) 28 [18–38] 19 [15–47] 23.5 [10–34.5] 15 [13–29] 0.085
Apo B-48/apo Bb 0.056 ± 0.0d 0.046 ± 0.02 0.015 ± 0.00 0.041 ± 0.02 0.035
Apo A-V/triglyceridesb 1.29 [1.02–1.73]e 1.10 [0.87–1.54]e 1.84 [1.60–2.48] 3.06 [2.24–4.27] 0.001
Postprandial parameters
Triglycerides iAUC 777.2 576.5 433 439.5 <0.001
(mg/dL/h) [548.5–1092.7]d, e [213–1028] [280–595.5] [243.5–568.5]
Triglycerides peak (mg/dL) 444.5 [353–562]d, e 444 [268–570]d, e 228 [188–291] 211 [180–231] <0.001
Triglycerides time to peak (h) 5 [4–6] 4 [4–5] 4 [4–5] 3 [3–4] 0.075
Apo B-48 iAUC (μg/mL/h)b 27.1 [15.3–49.3] 23.6 [11.6–29.3] 15 [10.8–23.4] 18.7 [8.7–24.6] 0.373
Apo B-48 peak (μg/mL)b 15.8 [11.6–22.2]d, e 14 [7–16.7] 4.2 [3.1–7.4] 7.4 [3.9–10] 0.002
Apo B-48 time to peak (h)b 6 [4–8]e 6 [4–8]e 5 [3.5–6] 4 [3–4] 0.024
Apo A-V iAUC 1132.9 707.8 363.8 145.1 0.002
(ng/mL/h)b [826.4–1474.7]d, e [72.6–1533.8] [145.0–480.5] [–5.8–453.0]
Apo A-V peak 603.4 459 323.2 358.6 <0.001
(ng/mL)b [534–673.7]d, e [382.9–613.9] [226.7–439.3] [299.2–423.9]
Apo A-V time to peak (h)b 6 [4–6]e 4 [4–6] 5 [3.5–6] 3 [3–4] 0.006
Data are expressed as means ± SD or medians [IQR]. HTG: hypertriglyceridemia defined as fasting triglycerides ≥150 mg/dL. Obesity defined as waist to hip ratio
(WHR) ≥0.92 in males and ≥0.85 in females. NTG: normotriglyceridemia defined as fasting triglycerides <150 mg/dL. aAll study subjects had apo B levels over the
90th percentile for the Mexican population and HTG and/or hypercholesterolemia at diagnosis; however, some of them showed inferior levels at the time of the
study due to the already known variability in the lipid profile associated with FCH.
bN = 44. cSignificantly different from individuals with HTG without obesity. dSignificantly different from individuals with NTG with obesity. eSignificantly different
from individuals with NTG without abdominal obesity.
Subjects characteristics according to the presence of hypertriglyceridemia and abdominal obesity.
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of postprandial lipemia [3,5,6,20]. The novel finding of
an independent association between fasting apo B-48
levels and postprandial lipemia in FCH indicate a poten-
tial role for intestinal-derived lipoproteins in postpran-
dial metabolism in individuals with FCH.
The relationship between abdominal obesity and post-
prandial lipemic response is less clear. Abdominal adi-
posity may be associated with liver fat deposition, adriving force for the overproduction of VLDL [11]. We
found a strong and independent association between
the WHR, a validated marker of abdominal obesity, and
postprandial lipemia. This result is consistent with the
finding that patients with fasting HTG and abdominal
obesity showed the greatest postprandial triglycerides
levels. Studies have confirmed that abdominal obesity, a
marker of visceral fat accumulation, is independently
associated with the magnitude of postprandial lipemia
Figure 2 Triglycerides iAUC, apo B-48 iAUC, and apo A-V iAUC
in subgroups according hypertriglyceridemia and abdominal
obesity. Box plots showing median levels of triglycerides iAUC, apo
B-48 iAUC, and apo A-V iAUC after the meal test. Boxes show
interquartile ranges, and bars represent highest and lowest values
P < 0.001 for triglycerides iAUC, P = 0.373 for apo B-48 iAUC, and
P = 0.002 for apo A-V iAUC with Kruskal Wallis test.
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our findings.
In patients with FCH the postprandial lipid response
was aggravated by abdominal obesity. A feasible mech-
anism for explaining our results is the oversaturation
and competition of chylomicrons and VLDL particles for
the same removal pathways [23]. This condition added
to other known cardiovascular risk factors may play a
key role in the increased risk for cardiovascular disease
seen in these individuals [1].
A novel finding of our report is the analysis of the fasting
and postprandial apo A-V response. Apo A-V postprandial
levels were mainly associated with the postprandial triglyc-
erides iAUC. Apo A-V is produced by the liver and is a
component of VLDL and HDL lipoprotein fractions [24].
It is presumed to be a factor in the activation of LPL result-
ing in increased triglycerides hydrolysis [8]. In individuals
with type 2 diabetes following a fat load, the apo A-V
postprandial response paralleled the increase in VLDL-
triglycerides and apo C-III levels. However, an association
between the apo A-V postprandial levels and LPL activity
was not found [25]. In FCH, polymorphisms on the
APOAV have been associated with increased fasting triglyc-
erides concentrations [26]. In this study, following the fat
meal, apo A-V levels increased and did not return to the
baseline at the end of the test. Interestingly, we found a sig-
nificant correlation between the apo B-48 and apo A-V
postprandial responses. We consider that this finding could
reflect an association of apo A-V not only with the VLDL
particles, but also with chylomicrons [27]. In the linear
regression analysis the only variable independently associ-
ated with the postprandial apo A-V response was the tri-
glycerides iAUC. Moreover, after analyzing the subgroups
according to their fasting triglyceride levels, the groups
with fasting HTG showed a significantly higher postpran-
dial apo A-V response in comparison to the normal fasting
triglycerides levels groups. These results confirm that apo
A-V is associated with the TRL in the postprandial period,
and is in line with the known regulation of VLDL metabol-
ism by apo A-V [8,26].
Our study has limitations. The cross-sectional design
only suggests associations and not causality. In addition,
we did not use DEXA or imaging studies to measure fat
mass and visceral adipose tissue volume. This would have
allowed more precise quantification of abdominal obes-
ity; however, the WHR is a validated marker of visceral
tissue accumulation [28]. Also, the WHR is an inform-
ative and simple measure to perform in everyday clinical
setting. Apo A-V polymorphisms were not investigated
in this study. Apo A-V was analyzed in a randomly se-
lected subgroup of the population; nevertheless, this sub-
group was representative of the complete sample studied.
Finally, we did not include a control group without FCH
to compare our results because our focus was to identify
Almeda-Valdes et al. BMC Endocrine Disorders 2014, 14:90 Page 8 of 9
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Conclusions
In conclusion, in individuals with FCH fasting apo B-48
concentration is the main factor associated with the
magnitude of postprandial lipemia. This response is po-
tentiated by abdominal obesity. Finally, the Apo A-V
postprandial levels are associated with the postprandial
triglycerides increment.
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